Please assess the completion status of the following clinical trial:

Trial Title: Cardiac Limitations in Chronic Obstructive Pulmonary Disease: Benefits of Bronchodilation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Chronic obstructive pulmonary disease (COPD) participants-~Inclusion criteria:~* Body Mass Index (BMI) \<36~* Moderate to severe COPD patient, (similar to or slightly better than Gold Guidelines Stage 2-3, forced expiratory volume in one second \[FEV_1\] \<60% of age predicted)~* Smoking history of 10 pack years or more~* Clinical diagnosis of COPD~* Not on daytime oxygen~Exclusion criteria:~* Clinical diagnosis of asthma~* Myocardial infarction within the last 6 months, or known ischemia~* Serious uncontrolled cardiac arrhythmia (i.e., atrial fibrillation or ventricular tachycardia) or hospitalization for heart failure within the previous year~* Known moderate to severe renal impairment~* Known moderate to severe symptomatic prostatic hypertrophy or bladder neck obstruction~* Known narrow angle glaucoma~* Current radiation or chemotherapy for a malignant condition~* Inability to give informed consent~* On systemic corticosteroids at unstable doses or on regular daily doses of 20 mg or more of prednisone (or equivalent)~* Not fully recovered from an exacerbation of COPD for at least 30 days~* Inability to perform light to moderate activity for orthopedic reasons or who significantly desaturated with exercise (percentage of available hemoglobin that is saturated with oxygen \[SaO_2\] \< 85% on screening test~Healthy controls -~Inclusion:~- Age and gender matched to COPD participants~Exclusion:~- Subjects who are unable to engage in exercise testing due to existing comorbidities

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Tiotropium (Type: EXPERIMENTAL): Participants with chronic obstructive pulmonary disease randomized to this arm received a once daily oral inhalation of 18 mcg tiotropium powder.
- Placebo (Type: PLACEBO_COMPARATOR): Participants with chronic obstructive pulmonary disease randomized to this arm received a once daily oral inhalation of placebo powder to match the standard active comparator dose.
- Healthy Controls (Type: NO_INTERVENTION): Healthy age and gender matched controls were recruited for comparing cardiovascular responses to participants with chronic obstructive pulmonary disease prior to the intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).